Mesalamine with MMX™ technology for the treatment of ulcerative colitis

References

• Neuman MG. Immune dysfunction in inflammatory bowel disease. Transl. Res.149, 173–186 (2007).
   PubMed Web of Science ®Google Scholar
• Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut53, V1–V16 (2004).
   PubMed Web of Science ®Google Scholar
• Ghosh S, Shand A, Ferguson A. Ulcerative colitis. Br. Med. J.320, 1119–1123 (2000).
   PubMed Web of Science ®Google Scholar
• Bitton A. Medical management of ulcerative proctitis, proctosigmoiditis, and left-sided colitis. Semin. Gastrointest. Dis.12, 263–274 (2001).
   PubMedGoogle Scholar
• Ullman TA. Preventing neoplastic progression in ulcerative colitis. J. Clin. Gastroenterol.39, S66–S69 (2005).
   Google Scholar
• Lakatos PL. Recent trends in the epidemiology of inflammatory bowel diseases: up or down? World J. Gastroenterol.12, 6102–6108 (2006).
   PubMed Web of Science ®Google Scholar
• Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology126, 1504–1517 (2004).
   PubMed Web of Science ®Google Scholar
• Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, practice parameters committee. Am. J. Gastroenterol.99, 1371–1385 (2004).
   PubMed Web of Science ®Google Scholar
• Sutherland L, MacDonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst. Rev.2, CD000544 (2006).
   Google Scholar
• Sutherland L, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst. Rev.CD000543 (2006).
   Google Scholar
• Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am. J. Gastroenterol.100, 1345–1353 (2005).
   PubMed Web of Science ®Google Scholar
• Qureshi AI, Cohen RD. Mesalamine delivery systems: do they really make much difference? Adv. Drug Deliv. Rev.57, 281–302 (2005).
   PubMed Web of Science ®Google Scholar
• Stenson WF, Lobos E. Sulfasalazine inhibits the synthesis of chemotactic lipids by neutrophils. J. Clin. Invest.69, 494–497 (1982).
   PubMed Web of Science ®Google Scholar
• Mahida YR, Lamming CE, Gallagher A, Hawthorne AB, Hawkey CJ. 5-aminosalicylic acid is a potent inhibitor of interleukin 1b production in organ culture of colonic biopsy specimens from patients with inflammatory bowel disease. Gut32, 50–54 (1991).
   PubMed Web of Science ®Google Scholar
• Rachmilewitz D, Karmeli F, Schwartz LW, Simon PL. Effect of aminophenols (5-ASA and 4-ASA) on colonic interleukin-1 generation. Gut33, 929–932 (1992).
   PubMed Web of Science ®Google Scholar
• Kaiser GC, Yan F, Polk DB. Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor κB activation in mouse colonocytes. Gastroenterology116, 602–609 (1999).
   PubMed Web of Science ®Google Scholar
• Egan LJ, Mays DC, Huntoon CJ et al. Inhibition of interleukin-1-stimulated NF-kB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity. J. Biol. Chem.274, 26448–26453 (1999).
   PubMed Web of Science ®Google Scholar
• Ahnfelt-Ronne I, Nielsen OH, Christensen A, Langholz E, Binder V, Riis P. Clinical evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid. Gastroenterology98, 1162–1169 (1990).
   PubMed Web of Science ®Google Scholar
• Rousseaux C, Lefebvre B, Dubuquoy L et al. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-g. J. Exp. Med.201, 1205–1215 (2005).
   PubMed Web of Science ®Google Scholar
• Lewis JD, Lichtenstein GR, Deren JJ et al. A randomized, placebo-controlled trial of the PPAR-γ ligand rosiglitazone for active ulcerative colitis. Gastroenterology13(24 Suppl. 1), (2007) (Abstract 639A).
   Google Scholar
• Marteau P, Probert CS, Lindgren S et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut54, 960–965 (2005).
   PubMed Web of Science ®Google Scholar
• Blonski W, Lichtenstein GR. Complications of biological therapy for inflammatory bowel diseases. Curr. Opin Gastroenterol.22, 30–43 (2006).
   PubMed Web of Science ®Google Scholar
• Katz JA. Treatment of inflammatory bowel disease with corticosteroids. Gastroenterol. Clin. North Am.33, 171–189vii (2004).
   PubMed Web of Science ®Google Scholar
• Siegel CA, Sands BE. Review article: practical management of inflammatory bowel disease patients taking immunomodulators. Aliment. Pharmacol. Ther.22, 1–16 (2005).
   PubMed Web of Science ®Google Scholar
• Cohen RD. Review article: evolutionary advances in the delivery of aminosalicylates for the treatment of ulcerative colitis. Aliment. Pharmacol. Ther.24, 465–474 (2006).
   PubMed Web of Science ®Google Scholar
• Moshkovska T, Mayberry JF. Duration of treatment with 5-aminosalicylic acid compounds. World J. Gastroenterol.13, 4310–4315 (2007).
   PubMed Web of Science ®Google Scholar
• Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet2, 892–895 (1977).
   PubMed Web of Science ®Google Scholar
• Hanauer SB. Review article: aminosalicylates in inflammatory bowel disease. Aliment. Pharmacol. Ther.20(Suppl. 4), 60–65 (2004).
   PubMed Web of Science ®Google Scholar
• Lim WC, Hanauer SB. Controversies with aminosalicylates in inflammatory bowel disease. Rev. Gastroenterol. Disord.4, 104–117 (2004).
   PubMedGoogle Scholar
• Courtney MG, Nunes DP, Bergin CF et al. Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis. Lancet339, 1279–1281 (1992).
   PubMed Web of Science ®Google Scholar
• Green JR, Gibson JA, Kerr GD et al. Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. ABACUS Investigator group. Aliment. Pharmacol. Ther.12, 1207–1216 (1998).
   PubMed Web of Science ®Google Scholar
• Levine DS, Riff DS, Pruitt R et al. A randomized, double-blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative coltis. Am. J. Gastroenterol.97, 1398–1407 (2002).
   PubMed Web of Science ®Google Scholar
• Pruitt RE, Hanson J, Safdi M et al. Balsalazide is superior to mesalamine in the time to improvment in signs and symptoms of acute mild-to-moderate ulcerative colitis. Am. J. Gastroenterol.97, 3078–3086 (2002).
   PubMed Web of Science ®Google Scholar
• De Vos M, Verdievel H, Schoonjans R, Praet M, Bogaert M, Barbier F. Concentrations of 5-ASA and Ac-5-ASA in human ileocolonic biopsy homogenates after oral 5-ASA preparations. Gut33, 1338–1342 (1992).
   PubMed Web of Science ®Google Scholar
• Ewe K, Press AG, Oestreicher M. The effect of food intake on the gastric emptying of gastric juice-resistant tablets and capsules. Dtsch. Med. Wochenschr.117, 287–290 (1992).
   PubMed Web of Science ®Google Scholar
• Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment. Pharmacol. Ther.23, 577–585 (2006).
   PubMed Web of Science ®Google Scholar
• Nugent SG, Kumar D, Rampton DS, Evans DF. Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs. Gut48, 571–577 (2001).
   PubMed Web of Science ®Google Scholar
• Rochester J, Abreu MT. Ulcerative colitis therapy: importance of delivery mechanisms. Rev. Gastroenterol. Disord.5, 215–222 (2005).
   PubMedGoogle Scholar
• Kane SV, Cohen RD, Aikens JE, Hanauer SB. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am. J. Gastroenterol.96, 2929–2933 (2001).
   PubMed Web of Science ®Google Scholar
• Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am. J. Med.114, 39–43 (2003).
   PubMed Web of Science ®Google Scholar
• Shale MJ, Riley SA. Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther.18, 191–198 (2003).
   PubMed Web of Science ®Google Scholar
• van Hees PA, van Tongeren JH. Compliance to therapy in patients on a maintenance dose of sulfasalazine. J. Clin. Gastroenterol.4, 333–336 (1982).
   PubMed Web of Science ®Google Scholar
• Levy RL, Feld AD. Increasing patient adherence to gastroenterology treatment and prevention regimens. Am. J. Gastroenterol.94, 1733–1742 (1999).
   PubMed Web of Science ®Google Scholar
• Loftus EV Jr. A practical perspective on ulcerative colitis: patients’ needs from aminosalicylate therapies. Inflamm. Bowel. Dis.12, 1107–1113 (2006).
   PubMed Web of Science ®Google Scholar
• Bernklev T, Jahnsen J, Aadland E et al. Health-related quality of life in patients with inflammatory bowel disease five years after the initial diagnosis. Scand. J. Gastroenterol.39, 365–373 (2004).
   PubMed Web of Science ®Google Scholar
• Casellas F, Arenas JI, Baudet JS et al. Impairment of health-related quality of life in patients with inflammatory bowel disease: a Spanish multicenter study. Inflamm. Bowel Dis.11, 488–496 (2005).
   PubMed Web of Science ®Google Scholar
• Han SW, McColl E, Barton JR, James P, Steen IN, Welfare MR. Predictors of quality of life in ulcerative colitis: the importance of symptoms and illness representations. Inflamm. Bowel Dis.11, 24–34 (2005).
   PubMed Web of Science ®Google Scholar
• Janke KH, Klump B, Gregor M, Meisner C, Haeuser W. Determinants of life satisfaction in inflammatory bowel disease. Inflamm. Bowel Dis.11, 272–286 (2005).
   PubMed Web of Science ®Google Scholar
• Lialda™ (mesalamine) delayed release tablets, prescribing information. Shire US Inc., Wayne PA USA (2007).
   Google Scholar
• Hanauer S, Sandborn W, Kornbluth A et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am. J. Gastroenterol.100, 2478–2485 (2005).
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sandborn WJ, Dallaire C et al. Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial. Can. J. Gastroenterol.21, 827–834 (2007).
   PubMed Web of Science ®Google Scholar
• Hanauer S, Schwartz J, Robinson M et al.; Pentasa Study Group. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Am. J. Gastroenterol.88, 1188–1197 (1993).
   PubMed Web of Science ®Google Scholar
• Brunner M, Greinwald R, Kletter K, Kvaternik H, Corrado M, Eichler HMM. Gastrointestinal transit and release of 5-aminosalicylic acid from 153Sm-labelled mesalazine pellets vs. tablets in male healthy volunteers. Aliment. Pharmacol. Ther.17, 1163–1169 (2003).
   PubMed Web of Science ®Google Scholar
• Wilding I, Behrens C, Tardif S, Wray H, Bias P, Albrecht W. Combined scintigraphic and pharmacokinetic investigation of enteric-coated mesalazine micropellets in healthy subjects. Aliment. Pharmacol. Ther.17, 1153–1162 (2003).
   PubMed Web of Science ®Google Scholar
• Farup P, Hinterleitner T, Lukas M et al. Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis. Inflamm. Bowel Dis.7, 237–242 (2001).
   PubMed Web of Science ®Google Scholar
• Raedler A, Behrens C, Bias P. Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis – results from a randomized-controlled trial. Aliment. Pharmacol. Ther.20, 1353–1363 (2004).
   PubMed Web of Science ®Google Scholar
• Prantera C, Viscido A, Biancone L, Francavilla A, Giglio L, Campieri M. A new oral delivery system for 5-ASA: preliminary clinical findings for MMx. Inflamm. Bowel Dis.11, 421–427 (2005).
   PubMed Web of Science ®Google Scholar
• Tenjarla S, Romasanta V, Zeijdner E, Villa R, Moro L. Release of 5-aminosalicylate from the MMX™ mesalamine tablet during transit through a simulated gastrointestinal tract system. Adv. Ther.24, 826–840 (2007).
   PubMed Web of Science ®Google Scholar
• Pierce D, Martin P, Kern M, Lees K. MMX™ mesalazine: a pharmacokinetic profile following single and multiple doses. Gut56, (2007) (Abstract MON-G-348).
   Google Scholar
• Pierce D, Martin P, Kern M, Lees K. MMX™ mesalazine: a pharmacokinetic evaluation of dose proportionality and the effect of food. Gut56, (2007) (Abstract MON-G-349).
   Google Scholar
• Sandborn WJ, Hanauer SB. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment. Pharmacol. Ther.17, 29–42 (2003).
   PubMed Web of Science ®Google Scholar
• Brunner M, Assandri R, Kletter K et al. Gastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation. Aliment. Pharmacol. Ther.17, 395–402 (2003).
   PubMed Web of Science ®Google Scholar
• Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ298, 82–86 (1989).
   PubMed Web of Science ®Google Scholar
• D’Haens G, Hommes D, Engels L et al. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a Phase II, dose-ranging study. Aliment. Pharmacol. Ther.24, 1087–1097 (2006).
   PubMed Web of Science ®Google Scholar
• Sutherland LR, Martin F, Greer S et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology92, 1894–1898 (1987).
   PubMed Web of Science ®Google Scholar
• Kamm MA, Sandborn WJ, Gassull M et al. Once-daily high concentration MMX mesalamine in active ulcerative colitis. Gastroenterology132, 66–75 (2007).
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Kamm MA, Boddu P et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin. Gastroenterol. Hepatol.5, 95–102 (2007).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Kamm MA, Lichtenstein GR, Lyne A, Butler T, Joseph RE. Multi Matrix System (MMX®) mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Aliment. Pharmacol. Ther.26, 205–215 (2007).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Karlstadt RG, Barrett K, Joseph RE. Time to intial symptom resolution withh MMX™ mesalamine therapy for active, mild-to-moderate ulcerative colitis. Am. J. Gastroenterol.102, (2007) (Abstract 619).
   Google Scholar
• Froslie KF, Jahnsen J, Moum BA, Vatn MH. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology133, 412–422 (2007).
   PubMed Web of Science ®Google Scholar
• Meucci G, Fasoli R, Saibeni S et al. Prognostic significance of endoscopy remission in patients with active ulcerative colitis treated with oral and topical mesalazine: preliminary results of a prospective, multicenter study. Gastroenterology130, A-197 (2006) (Abstract S1302).
   Google Scholar
• Gassull M, Lichtenstein G, Sandborn W, Kamm M, Barrett K, Joseph R. MMX Mesalazine is an effective treatment for men and women with mild-to-moderate, active ulcerative colitis. J. Crohn’s Colitis Suppl.1(18), P057 (2007).
   Google Scholar
• Kamm MA, Lichtenstein GR, Sandborn WJ et al. SPD476, a novel formulation of 5-ASA given once or twice daily, is effective for the induction of remission of left-sided and extensive ulcerative colitis: an analysis of combined data from two pivotal, randomized, placebo-controlled Phase III studies. Gastroenterology130(4 Suppl. 2), A484 (2006) (Abstract T1148).
   Google Scholar
• Lichtenstein GR, Kamm MA, Sandborn WJ et al. Once- and twice-daily SPD476, a novel, high-strength formulation of 5-ASA, induces remission of both mild and moderate ulcerative colitis: a prespecified analysis of combined data from two pivotal, randomized, placebo-controlled, Phase III studies. Gastroenterology130(4 Suppl. 2), A-484 (2006) (Abstract T1147).
   Google Scholar
• Sandborn WJ, Kamm MA, Lichtenstein GR et al. SPD476, a novel, high-strength 5-ASA formulation induces remission of active, mild-to-moderate ulcerative colitis in subjects that are switched from low-dose oral 5-ASA therapy or are 5-ASA naive: an analysis of pooled data from two Phase III studies. Gastroenterology130(4 Suppl. 2), A482 (2006) (Abstract T1139).
   PubMed Web of Science ®Google Scholar
• Kamm MA, Lichtenstein GR, Sandborn WJ et al. Randomized trial of once- or twice-daily MMX™ mesalamine for maintenance of remission in ulcerative colitis. Gut (2008) (In Press).
   Google Scholar
• Kamm MA, Colombel J.-F, Kornbluth A et al. A randomized comparison of once- versus twice-daily MMX mesalamine for the maintenance of remission in mild-to-moderate ulceratice colitis. Gastroenterology132, A510 (2007) (Abstract T1296).
   Google Scholar
• Lichtenstein GR, Kamm MA, Panaccione R, Barrett K, Lees K, Joseph R. The effect of prolonged therapy with MMX™ mesalamine in patients with acute, mild-to-moderate ulcerative colitis. Am. J. Gastroenterol.102, S2 (2007) (Abstract 953).
   Google Scholar
• Kruis W, Bar-Meir S, Feher J et al. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. Clin. Gastroenterol. Hepatol.1, 36–43 (2003).
   PubMed Web of Science ®Google Scholar
• Panaccione R, Kamm M, Karlstadt RG, Diebold R, Barrett K, Joseph RE. Once- or twice-daily MMX™ mesalamine for the maintenance of remission of mild or moderate ulcerative colitis. Am. J. Gastroenterol.102, (2007) (Abstract 950).
   Google Scholar
• Lichtenstein G, Kamm MA, Karlstadt RG, Diebold R, Barrett K, Joseph R. MMX™ mesalamine is effective for the maintenance of ulcerative colitis remission in both left sided and extensive disease. Am. J. Gastroenterol.102(Suppl. 2), 1049–1058 (2007) (Abstract 949).
   Google Scholar
• Hanauer SB, Kamm MA, Diebold R, Barrett K, Joseph RE. Long-term remission rates in patients with mild-to-moderate ulcerative colitis who require an MMX™ mesalamine dose increase to induce initial remission. Am. J. Gastroenterol.102, (2007) (Abstract 614).
   PubMedGoogle Scholar
• Sandborn WJ, Karlstadt RG, Barrett K, Joseph RE. MMX™ mesalamine is effective for the maintenance of remission of mild-to-moderate ulcerative colitis irrespective of patients’ previous relapse history. Am. J. Gastroenterol.102, (2007) (Abstract 283).
   Google Scholar
• Lichtenstein GR, Diebold R, Karlstadt RG, Barrett K, Joseph RE. Patients with quiescent mild-to-moderate ulcerative colitis receiving a multiple-daily dose 5-aminosalicylic acid formulation can maintain remission with once- or twice-daily MMX® mesalamine. Gastroenterology132, A-510 (2007) (Abstract T1295).
   Google Scholar
• Lichtenstein G, Katz S, Christenson A, Lees K, Barrett K, Joseph R. Safety of MMX mesalamine, a novel, once-daily 5-aminosalicylic acid (5-ASA) formulation for the treatment of ulcerative colitis, following 8 weeks’ treatment: data from three Phase III studies. J. Am. Pharm. Assoc.47, 210–211 (2007).
   Google Scholar
• Adachi E, Okazaki K, Matsushima Y et al. Acute pancreatitis secondary to 5-aminosalicylic acid therapy in a patient with ulcerative colitis. Int. J. Pancreatol.25, 217–221 (1999).
   PubMedGoogle Scholar
• Decocq G, Gras-Champel V, Vrolant-Mille C et al. Acute pancreatitis induced by drugs derived from 5-aminosalicylic acid: case report and review of the literature. Therapie54, 41–48 (1999).
   PubMed Web of Science ®Google Scholar
• Lankisch PG, Droge M, Gottesleben F. Drug induced acute pancreatitis: incidence and severity. Gut37, 565–567 (1995).
   PubMed Web of Science ®Google Scholar
• Marteau P, Nelet F, Le Lu M, Devaux C. Adverse events in patients treated with 5-aminosalicyclic acid: 1993–1994 pharmacovigilance report for Pentasa in France. Aliment. Pharmacol. Ther.10, 949–956 (1996).
   PubMed Web of Science ®Google Scholar
• Kamm MA, Lichtenstein GR, Sandborn WJ, Barrett K, Joseph R. MMX™ mesalazine is well tolerated during 12 months’ maintenance treatment of mild-to-moderate ulcerative colitis. Gut56, A113 (2007).
   Google Scholar